ACRV — Acrivon Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $56.93m
- -$80.49m
- 24
- 53
- 43
- 33
Annual cashflow statement for Acrivon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.31 | -16.2 | -31.2 | -60.4 | -80.6 |
| Depreciation | |||||
| Non-Cash Items | 2.17 | 1.9 | 2.22 | 9.07 | 11.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.317 | 0.328 | -1.53 | 8.14 | 2.44 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -2.8 | -14 | -30.1 | -42.6 | -65.7 |
| Capital Expenditures | -0.015 | -0.238 | -2.17 | -1.29 | -2.77 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -140 | 52 | -49 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.015 | -0.238 | -142 | 50.7 | -51.8 |
| Financing Cash Flow Items | — | — | 99.8 | -1.3 | -2.52 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.89 | 112 | 102 | -1.55 | 121 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.071 | 98 | -70.1 | 6.52 | 3.59 |